-+ 0.00%
-+ 0.00%
-+ 0.00%

BioVie Phase 2 Trial Links Long COVID Biomarker Subgroups to Different Bezisterim Responses

PUBT·11/16/2026 13:06:12
Listen to the news
BioVie Phase 2 Trial Links Long COVID Biomarker Subgroups to Different Bezisterim Responses
  • BioVie presented exploratory Phase 2 ADDRESS-LC findings for bezisterim in Long COVID on Nov. 13, 2026, at a conference in Nice, France.
  • The 203-participant trial showed improvement trends, but no efficacy outcomes reached statistical significance in the overall population over 12 weeks.
  • Patients with elevated inflammation showed significant cognitive improvement; those with low white blood cell levels showed larger fatigue and post-exertional malaise treatment effects.
  • Bezisterim significantly reduced circulating neuropeptide Y, supporting further evaluation as a potential treatment-response marker rather than a validated diagnostic biomarker.
  • Safety and tolerability were comparable to placebo, with no serious treatment-emergent adverse events in the bezisterim group.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160800PRIMZONEFULLFEED9877988) on November 16, 2026, and is solely responsible for the information contained therein.